Benefits of Using Dapsone in Patients Hospitalized with COVID-19.

Autor:	Kanwar BA; Department of Intensive Care Unit and Neonatal Intensive Care, Hunt Regional Hospital, Greenville, TX 75401, USA., Khattak A; Department of Intensive Care Unit and Neonatal Intensive Care, Hunt Regional Hospital, Greenville, TX 75401, USA., Balentine J; Department of Intensive Care Unit and Neonatal Intensive Care, Hunt Regional Hospital, Greenville, TX 75401, USA., Lee JH; Science and Research Center, Seoul National University College of Medicine, Seoul 03080, Korea., Kast RE; IIAIGC Study Center, Burlington, VT 05408, USA.
Jazyk:	angličtina
Zdroj:	Vaccines [Vaccines (Basel)] 2022 Jan 26; Vol. 10 (2). Date of Electronic Publication: 2022 Jan 26.
DOI:	10.3390/vaccines10020195
Abstrakt:	Since the start of the SARS-CoV-2 pandemic, refractory and relentless hypoxia as a consequence of exuberant lung inflammation and parenchymal damage remains the main cause of death. We have earlier reported results of the addition of dapsone in this population to the standard of care. We now report a further chart review of discharge outcomes among patients hospitalized for COVID-19. The 2 × 2 table analysis showed a lower risk of death or discharge to LTAC (Long term acute care) (RR = 0.52, 95% CI: 0.32 to 0.84) and a higher chance of discharge home (RR = 2.7, 95% CI: 1.2 to 5.9) among patients receiving dapsone compared to those receiving the usual standard of care. A larger, blinded randomized trial should be carried out urgently to determine if dapsone indeed improves outcomes in COVID-19.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu